BridgeBio Pharma said on Monday its experimental drug for a rare muscle disorder, which currently has no approved treatments, showed improvements in motor and lung function in a late-stage trial, ...
New interim data from a Phase III trial puts the company on track to file for FDA approval next year in an indication that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback